We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+54.45%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$4.6B
AUM Growth
+$1.51B
Cap. Flow
+$217M
Cap. Flow %
4.71%
Top 10 Hldgs %
30.3%
Holding
146
New
24
Increased
37
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$75.3M
2
TT icon
Trane Technologies
TT
+$39.3M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$35.1M
4
EXAS
Exact Sciences
EXAS
+$27.8M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.1M

Top Sells

Rank Stock Value
1
XYL icon
Xylem
XYL
+$51.6M
2
TWLO icon
Twilio
TWLO
+$48M
3
ZGNX
Zogenix, Inc.
ZGNX
+$45M
4
VRNS icon
Varonis Systems
VRNS
+$26.7M
5
SAGE
Sage Therapeutics
SAGE
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 45.14%
2 Technology 22.43%
3 Industrials 8.89%
4 Consumer Discretionary 7.31%
5 Communication Services 3.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
26
Idexx Laboratories
IDXX
$44.1B
$58.1M 1.26%
176,000
+33,000
+23% +$9.55M
SMAR
27
DELISTED
Smartsheet Inc.
SMAR
$56.7M 1.23%
1,113,000
+166,000
+18% +$8.45M
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$53.5M 1.16%
436,000
– –
AIMT
29
DELISTED
Aimmune Therapeutics
AIMT
$53.4M 1.16%
3,193,117
-657,883
-17% -$11.2M
IPHI
30
DELISTED
INPHI CORPORATION
IPHI
$52.9M 1.15%
450,000
– –
ODFL icon
31
Old Dominion Freight Line
ODFL
$44.2B
$52.6M 1.14%
620,400
+193,400
+45% +$14.7M
HUBS icon
32
HubSpot
HUBS
$11.9B
$52M 1.13%
232,000
-100,000
-30% -$18M
TREX icon
33
Trex
TREX
$4.56B
$48.6M 1.06%
748,000
+150,000
+25% +$8M
VMC icon
34
Vulcan Materials
VMC
$35.2B
$46.2M 1%
398,400
-3,300
-0.8% -$361K
RNG icon
35
RingCentral
RNG
$4.48B
$44.2M 0.96%
155,000
+34,000
+28% +$8.6M
CCI icon
36
Crown Castle
CCI
$33.4B
$44.1M 0.96%
263,400
-2,500
-0.9% -$403K
BEP icon
37
Brookfield Renewable
BEP
$9.9B
$43.9M 0.95%
1,719,249
– –
NBIX icon
38
Neurocrine Biosciences
NBIX
$18.7B
$43.7M 0.95%
357,800
+4,800
+1% +$530K
ZNTL icon
39
Zentalis Pharmaceuticals
ZNTL
$350M
$42.5M 0.92%
+914,705
New +$35.1M
COLL icon
40
Collegium Pharmaceutical
COLL
$1.17B
$42.5M 0.92%
2,427,976
– –
TT icon
41
Trane Technologies
TT
$97.3B
$42M 0.91%
472,000
+452,200
+2,284% +$39.3M
APTV icon
42
Aptiv
APTV
$12.3B
$41.8M 0.91%
537,000
-19,500
-4% -$1.34M
DHI icon
43
D.R. Horton
DHI
$40.7B
$40.5M 0.88%
730,200
+71,000
+11% +$3.44M
MNTA
44
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$40.3M 0.88%
1,212,000
– –
VRSK icon
45
Verisk Analytics
VRSK
$26.1B
$37.4M 0.81%
219,500
+61,500
+39% +$9.72M
KALA icon
46
KALA BIO
KALA
$13.6M
$36.3M 0.79%
1,381
+199
+17% +$5.64M
BPMC
47
DELISTED
Blueprint Medicines
BPMC
$36M 0.78%
462,000
– –
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$34.4M 0.75%
301,000
– –
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
$33.8M 0.73%
535,000
– –
TECX
50
Tectonic Therapeutic
TECX
$538M
$33.2M 0.72%
158,776
– –
1
2
3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Eventide Asset Management held 146 positions worth $4.6B, up 49% from $3.09B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Eventide Asset Management deployed $217M of net new capital in Q2 2020, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Pliant Therapeutics: 2,838,125 shares worth $88.4M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 44% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Twilio, an estimated $48M trimmed.

  • Eventide Asset Management's largest Q2 2020 buy was Pliant Therapeutics: 2,838,125 shares worth $88.4M.
  • Eventide Asset Management added most to Trane Technologies in Q2 2020, an estimated $39.3M increase.
  • Eventide Asset Management's biggest Q2 2020 reduction was Twilio, cutting an estimated $48M.
  • Eventide Asset Management fully exited Xylem in Q2 2020, selling an estimated $51.6M.
  • Eventide Asset Management's ten largest holdings make up 30% of its $4.6B portfolio in Q2 2020.
  • Eventide Asset Management opened 24 new positions and closed 12 in Q2 2020.
  • Eventide Asset Management's portfolio value rose 49% quarter-over-quarter to $4.6B.

Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.